Alnylam/Roche’s Zilebesiran Affirms Efficacy, But Commercially Relevant Data Await

Alnylam Pharmaceuticals Inc.’s data from the Phase II KARDIA-1 study of its RNA interference drug zilebesiran affirm efficacy data published in July from a Phase I study, but data from another Phase II study, KARDIA-2, might better inform about the drug’s commercial opportunity. To that end, the company has partnered with Roche Holding AG and hopes to benefit from the Swiss drug maker’s buy-and-bill capabilities.

Alnylam announced the results of KARDIA-1, testing zilebesiran monotherapy against placebo in 394 patients, on 7 September